SELLAS Life Sciences Group, Inc.
NASDAQSLS cost to borrow surges 138% in one week to 142.4%, driven by near-zero share availability and heavy short demand in stressed biotech lending market.
Short interest % of float, cost to borrow, utilization, and put/call ratio for SLS are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
SELLAS Life Sciences has crossed into territory where the lending market offers almost nothing to new short sellers. Availability has collapsed to 0.04% — effectively zero. Every share in the lending pool is now out on…
SELLAS Life Sciences Group has gained 45% in a week, yet short sellers have barely moved — and the borrow market is tightening again. A week ago this note flagged the tension between a rallying biotech and an…
Snapshot as of 5 Jul 2026
SELLAS Life Sciences Group just beat Q1 estimates and is weeks from a pivotal trial readout — and more than 30% of its free float is still held short. That tension is the whole story this week. SLS reported Q1 EPS of…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SLS — free to start on ORTEX.
Sign up for free →Open SLS on ORTEX